Xenon Pharmaceuticals (XENE) Cash from Investing Activities (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Cash from Investing Activities data on file, last reported at -$407.3 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$407.3 million, down 1280.19% year-over-year; the trailing twelve-month figure through Mar 2026 was -$223.8 million (down 192.21% YoY), and the FY2025 annual result was $218.0 million, up 32.12% from the prior year.
• Cash from Investing Activities declined to -$407.3 million in Q1 2026 per XENE's latest filing, from $62.7 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $109.2 million in Q2 2024 and troughed at -$407.3 million in Q1 2026.
• A 5-year average of -$25.2 million and a median of $27.9 million in 2023 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities tumbled 1943.03% in 2023, then surged 7637.15% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at -$11.7 million in 2022, then plunged by 1943.03% to -$239.8 million in 2023, then jumped by 141.08% to $98.5 million in 2024, then plunged by 36.35% to $62.7 million in 2025, then sank by 749.6% to -$407.3 million in 2026.
• Business Quant data shows XENE's Cash from Investing Activities at -$407.3 million in Q1 2026, $62.7 million in Q4 2025, and $38.5 million in Q3 2025.